Kenneth Berger, MD
Urology · Clarkston, WANPI 1366407942
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Intuitive Surgical at 52.0% of the total. Reporting peaked in 2019 at $5,126 and has fallen 85.1% since, to $762 in 2025.
Across 169 payments — averaging $54.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- Astellas Pharma US Inc$649
- Sumitomo Pharma America, Inc.$572
- Cook Medical LLC$357
- AbbVie$331
- Progenics Pharmaceuticals, Inc.$322
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$4,00043%
- Travel & lodging$6897%
- Food & beverage$4,11645%
- Education$4425%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 9 | $4,809 |
| Astellas Pharma US Inc | 24 | $649 |
| Sumitomo Pharma America, Inc. | 26 | $572 |
| Cook Medical LLC | 3 | $357 |
| AbbVie(2 entities) | 13 | $331 |
| Progenics Pharmaceuticals, Inc. | 5 | $322 |
| Boston Scientific | 10 | $299 |
| Johnson & Johnson | 8 | $271 |
| AstraZeneca | 8 | $227 |
| Pfizer | 10 | $195 |
| Urovant Sciences Inc | 8 | $136 |
| Dendreon Pharmaceuticals LLC | 4 | $120 |
| Olympus America Inc. | 2 | $99 |
| Procept Biorobotics Corporation | 3 | $96 |
| 180 Medical, Inc. | 4 | $87 |
| Myriad Genetic Laboratories, Inc. | 3 | $86 |
| Medtronic(2 entities) | 2 | $81 |
| Myovant Sciences Inc. | 4 | $73 |
| KARL Storz Endoscopy-america | 1 | $50 |
| Coloplast | 3 | $49 |
| Merck | 3 | $47 |
| Endo Pharmaceuticals Inc. | 2 | $46 |
| Baxter Healthcare | 1 | $43 |
| Ambu Inc. | 1 | $35 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $21 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Laborie Medical Technologies Corp. | 1 | $20 |
| Immunitybio, Inc. | 1 | $19 |
| Accord Healthcare, Inc. | 1 | $19 |
| Conmed Corporation | 1 | $16 |
| Axonics, Inc. | 1 | $15 |
| Teleflex LLC | 1 | $14 |
| Photocure Inc | 1 | $13 |
| Travere Therapeutics, Inc. | 3 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,670
- PYLARIFY$246
- LITHO 150$220
- Cook$137
- Lupron Depot$113
How this compares
$9,248 in reported general payments places this provider in the 85th percentile of 274 urology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 23 | $353,052 |
| MyrbetriqMirabegron | 159 | $88,488 |
| OrgovyxRelugolix | 29 | $78,345 |
| GemtesaVibegron | 81 | $43,113 |
| Tamsulosin Hcl | 740 | $12,387 |
| Potassium Citrate ErPotassium Citrate | 39 | $5,262 |
| Estradiol | 73 | $4,151 |
| Finasteride | 298 | $3,828 |
| Oxybutynin Chloride ErOxybutynin Chloride | 115 | $3,490 |
| Solifenacin Succinate | 82 | $2,732 |
| Methenamine Hippurate | 20 | $2,152 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 115 | $1,913 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 87 | $1,397 |
| Dutasteride | 35 | $1,141 |
| Trospium Chloride | 14 | $682 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $649 | $441,540182 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $572 | $121,458110 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 274 urology providers in Washington.
Other urology in Clarkston
- James PorterSeattle$471K
- Marah HehemannSeattle$213K
- Raymond LanceSpokane$211K
- Thomas WalshSeattle$186K
- Alvaro LucioniSeattle$148K
- Una LeeSeattle$116K
- George SchadeSeattle$78K
- Kevin OstrowskiKirkland$64K
- Marco SalazarEdmonds$58K
- Anthony BuiVancouver$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.